1.
Challenges associated with curcumin therapy in Alzheimer disease.
Belkacemi A, Doggui S, Dao L, Ramassamy C.
Expert Rev Mol Med. 2011 Nov 4;13:e34.
PMID: 22051121 [PubMed - in process]
Related citations
2.
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.
Jucker M, Walker LC.
Ann Neurol. 2011 Oct;70(4):532-40. doi: 10.1002/ana.22615.
PMID: 22028219 [PubMed - in process]
Related citations
3.
Truncation of tau at E391 promotes early pathologic changes in transgenic mice.
McMillan PJ, Kraemer BC, Robinson L, Leverenz JB, Raskind M, Schellenberg G.
J Neuropathol Exp Neurol. 2011 Nov;70(11):1006-19. doi: 10.1097/NEN.0b013e31823557fb.
PMID: 22002427 [PubMed - indexed for MEDLINE]
Related citations
4.
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.
Braak H, Thal DR, Ghebremedhin E, Del Tredici K.
J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9. doi: 10.1097/NEN.0b013e318232a379.
PMID: 22002422 [PubMed - indexed for MEDLINE]
Related citations
5.
Predicting MCI outcome with clinically available MRI and CSF biomarkers.
Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative.
Neurology. 2011 Oct 25;77(17):1619-28. Epub 2011 Oct 12.
PMID: 21998317 [PubMed - indexed for MEDLINE]
Related citations
6.
Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356.
Dolan PJ, Jin YN, Hwang W, Johnson GV.
FEBS Lett. 2011 Nov 4;585(21):3424-9. Epub 2011 Oct 5.
PMID: 21983102 [PubMed - indexed for MEDLINE]
Related citations
7.
Distinct temporal and anatomical distributions of amyloid-β and tau abnormalities following controlled cortical impact in transgenic mice.
Tran HT, Sanchez L, Esparza TJ, Brody DL.
PLoS One. 2011;6(9):e25475. Epub 2011 Sep 29.
PMID: 21980472 [PubMed - in process] Free PMC Article
Related citations
8.
Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.
Arch Neurol. 2011 Sep;68(9):1145-51.
PMID: 21911695 [PubMed - indexed for MEDLINE]
Related citations
9.
Structural impact of proline-directed pseudophosphorylation at AT8, AT100, and PHF1 epitopes on 441-residue tau.
Bibow S, Ozenne V, Biernat J, Blackledge M, Mandelkow E, Zweckstetter M.
J Am Chem Soc. 2011 Oct 12;133(40):15842-5. Epub 2011 Sep 15.
PMID: 21910444 [PubMed - in process]
Related citations
10.
[The role of CSF markers in the early diagnosis of Alzheimer's disease].
Vos SJ, Visser PJ, Verhey FR.
Tijdschr Psychiatr. 2011;53(9):647-53. Dutch.
PMID: 21898322 [PubMed - indexed for MEDLINE] Free Article
Related citations
11.
Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.
Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer's Disease Neuroimaging Initiative.
Arch Neurol. 2011 Aug;68(8):1013-9.
PMID: 21825236 [PubMed - indexed for MEDLINE]
Related citations
12.
Application of immunosignatures to the assessment of Alzheimer's disease.
Restrepo L, Stafford P, Magee DM, Johnston SA.
Ann Neurol. 2011 Aug;70(2):286-95. doi: 10.1002/ana.22405.
PMID: 21823156 [PubMed - indexed for MEDLINE]
Related citations
13.
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.
Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.
PMID: 21823155 [PubMed - indexed for MEDLINE]
Related citations
14.
Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model.
Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM.
J Mol Neurosci. 2011 Nov;45(3):432-7. Epub 2011 Aug 6.
PMID: 21822709 [PubMed - in process]
Related citations
15.
Proposal for Alzheimer's diagnosis using molecular buffer and bus network.
Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Saktioto T, Ali J, Yupapin PP.
Int J Nanomedicine. 2011;6:1209-16. Epub 2011 Jun 14.
PMID: 21822383 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
16.
Suppression of a neocortical potassium channel activity by intracellular amyloid-β and its rescue with Homer1a.
Yamamoto K, Ueta Y, Wang L, Yamamoto R, Inoue N, Inokuchi K, Aiba A, Yonekura H, Kato N.
J Neurosci. 2011 Aug 3;31(31):11100-9.
PMID: 21813671 [PubMed - indexed for MEDLINE]
Related citations
17.
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.
Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, Iqbal K.
FEBS Lett. 2011 Sep 2;585(17):2653-9. Epub 2011 Jul 28.
PMID: 21806989 [PubMed - indexed for MEDLINE]
Related citations
18.
Ligand polarizability contributes to tau fibril binding affinity.
Jensen JR, Cisek K, Honson NS, Kuret J.
Bioorg Med Chem. 2011 Sep 1;19(17):5147-54. Epub 2011 Jul 19.
PMID: 21803586 [PubMed - indexed for MEDLINE]
Related citations
19.
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.
Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW.
Lancet Neurol. 2011 Sep;10(9):785-96. Epub 2011 Jul 27.
PMID: 21802369 [PubMed - indexed for MEDLINE]
Related citations
20.
FKBP immunophilins and Alzheimer's disease: a chaperoned affair.
Cao W, Konsolaki M.
J Biosci. 2011 Aug;36(3):493-8. Review.
PMID: 21799260 [PubMed - indexed for MEDLINE]
No comments:
Post a Comment